Eltrombopag Olamine: A Comprehensive Guide for API Importers, Manufacturers, and Compounding Pharmacies
Eltrombopag Olamine represents a paradigm shift in the treatment of thrombocytopenia.
As a non-peptide thrombopoietin receptor agonist (TPO-RA), it has provided a lifeline to patients suffering from chronic immune thrombocytopenia (ITP), aplastic anemia, and hepatitis C-associated thrombocytopenia.
For pharmaceutical industry professionals—API importers, medicine manufacturers, and compounding pharmacies—understanding this molecule is not just about clinical data; it’s about navigating a complex landscape of global supply chains, stringent quality control, regulatory hurdles, and evolving market opportunities.
What is Eltrombopag?
Eltrombopag is a small, synthetic molecule classified as a thrombopoietin receptor agonist. Its chemical name is 3’-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2’-hydroxy-3-biphenylcarboxylic acid.
The active ingredient used in pharmaceutical preparations is its ethanolamine salt, Eltrombopag Olamine, which improves its solubility and bioavailability.
Chemically, it is a biphenyl hydrazone, distinct from endogenous thrombopoietin, which is a large glycoprotein.
This small molecular size is a critical differentiator.
It allows Eltrombopag to bind to the transmembrane domain of the TPO receptor (c-Mpl) on megakaryocytes, a site different from the binding site of the natural hormone.
This unique mechanism avoids competition with endogenous TPO, reducing the risk of cross-reactivity and neutralizing antibodies.
For API importers and manufacturers, the key takeaway is its classification: a Biopharmaceutical Classification System (BCS) Class IV drug.
This means it has both low solubility and low permeability.
This characteristic is the most critical factor influencing formulation strategies.
It dictates the need for sophisticated techniques to enhance bioavailability, making the choice of excipients and the manufacturing process paramount for creating a therapeutically effective and bioequivalent product.
What are the brand names of Eltrombopag?
Eltrombopag is marketed globally under several brand names, a crucial detail for market analysis and sourcing inquiries.
Promacta: The primary brand name used in the United States, Canada, and several other countries. This is the most recognized trademark.
Revolade: The brand name used throughout Europe, the United Kingdom, Asia, and many other international markets.
Other Regional Names: It may be sold under different names in specific countries due to licensing agreements.
For compounding pharmacies and generic manufacturers, understanding the brand landscape is essential for patient communication and for identifying the origin of reference listed drugs (RLD) for bioequivalence studies.
When sourcing the API, it is almost exclusively referred to by its International Nonproprietary Name (INN), Eltrombopag, or its salt form, Eltrombopag Olamine.
What is Eltrombopag used for?
Eltrombopag is specifically indicated for the treatment of thrombocytopenia (low platelet count) in various patient populations. Its approved uses have expanded since its initial launch, reflecting its efficacy and safety profile.
Chronic Immune Thrombocytopenia (ITP): This was its first approved indication. It is used in splenectomized adults and children (ages 1 year and older) who have had an insufficient response to corticosteroids, immunoglobulins, or other first-line therapies. It is also used in non-splenectomized patients where surgery is contraindicated.
Thrombocytopenia in Patients with Hepatitis C Virus (HCV) Infection: Eltrombopag is used to allow the initiation and maintenance of interferon-based therapy in patients with HCV-associated thrombocytopenia, where the degree of thrombocytopenia prevents therapy or warrants dose reduction. This use requires careful liver monitoring.
Severe Aplastic Anemia (SAA): It is approved for first-line treatment in combination with standard immunosuppressive therapy (IST) for patients with severe aplastic anemia. It is also used as a second-line monotherapy for patients who have had an insufficient response to IST.
Other Off-Label and Investigational Uses: Research is ongoing for its use in chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), and other bone marrow failure disorders. This represents a significant future growth area for the API market.
How Eltrombopag Works? (Mechanism of Action)
The mechanism of action (MOA) of Eltrombopag is a masterpiece of targeted pharmacology and is fundamental for anyone involved in its production or application.
Unlike recombinant human thrombopoietin (rhTPO), which mimics the entire natural protein, Eltrombopag is a small molecule agonist.
It binds selectively to the transmembrane domain of the human TPO receptor (c-Mpl) on the surfaces of megakaryocytes and megakaryocytic precursors in the bone marrow.
This binding triggers intracellular signaling cascades, primarily the JAK-STAT and MAPK pathways, which promote:
Proliferation and differentiation of megakaryocyte progenitor cells.
Maturation of megakaryocytes.
Increased production and release of platelets into the bloodstream.
Critical Industrial Insight: Its MOA is hepatocyte-independent for its primary effect, but it is metabolized in the liver.
This is why hepatic monitoring is a black box warning and a critical part of the risk management strategy for any manufacturer.
Furthermore, because it does not compete with endogenous TPO, it has a lower immunogenic potential, a significant advantage in terms of drug safety, and a reduced risk of complications during long-term therapy.
Eltrombopag Dosage and Administration
For medicine manufacturers and compounding pharmacies, understanding dosage forms and administration guidelines is crucial for product development and effective patient counseling.
Available Dosage Forms: The commercial product is available in film-coated tablets (12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg of eltrombopag free acid equivalent) and as a powder for oral suspension (12.5 mg and 25 mg packets). The development of the oral suspension was a direct result of the challenges posed by its BCS Class IV properties and the need for a pediatric formulation.
Dosing is Highly Individualized: the goal is to achieve and maintain a platelet count of≥ 50 x 10^9/L to reduce the risk of bleeding.
ITP: Starting dose is usually 50 mg once daily (25 mg for patients of East Asian heritage or those with hepatic impairment). The dose is adjusted in 25 mg increments every 2 weeks based on the platelet response.
HCV: Starting dose is 25 mg once daily.
SAA: Starting dose is 150 mg once daily for patients ≥ 12 years, and 75 mg once daily for patients 6-11 years.
Crucial Administration Instructions: This is a significant point for formulation scientists. Eltrombopag has very poor and variable bioavailability when taken with food, especially calcium-rich (dairy products) and polyvalent cation-containing (antacids, mineral supplements, iron) foods. Therefore, it must be administered on an empty stomach, either 1 hour before or 2 hours after a meal. This is a direct consequence of its chelating properties and low solubility, profoundly impacting excipient selection and patient use instructions for both compounded and generic products.
Eltrombopag Precautions and Drug Interactions
A robust understanding of the safety profile is non-negotiable for any entity handling this API.
Black Box Warnings (U.S. FDA):
Hepatotoxicity: Eltrombopag can cause severe and potentially fatal hepatotoxicity. Serum liver tests (ALT, AST, Bilirubin) must be monitored before initiation, every 2 weeks during dose adjustment, and monthly once a stable dose is achieved.
Risk of Thrombotic Complications: Excessively high platelet counts (>200 x 10⁹/L) increase the risk of thrombotic events (e.g., deep vein thrombosis, pulmonary embolism, stroke). Dose reduction or interruption is necessary if the count rises too high.
Cataracts: Development or progression of cataracts has been reported. Baseline and periodic ophthalmological examinations are required.
Significant Drug Interactions:
Polyvalent Cations: As mentioned, this is the most critical interaction for formulators. Eltrombopag chelates polyvalent cations like calcium, iron, zinc, magnesium, and aluminum. Concomitant administration with antacids, dairy products, mineral supplements, or foods high in these cations will severely reduce its absorption. A 4-hour separation is recommended.
CYP Enzyme Interactions: Eltrombopag is a substrate of CYP1A2 and CYP2C8, and an inhibitor of OATP1B1 and BCRP. It may interact with drugs like clopidogrel, repaglinide, rosuvastatin, and atorvastatin. Dose monitoring may be necessary.
Other TPO-RAs: Concurrent use with other thrombopoietin receptor agonists is not recommended.
What are the side effects of Eltrombopag?
A comprehensive adverse effect profile is vital for risk-benefit analysis and patient information leaflets.
Very Common (≥1/10):
Nausea, vomiting, diarrhea
Headache
Increased liver enzymes (ALT, AST)
Rash, alopecia (hair loss)
Common (≥1/100 to <1/10):
Dry mouth, dyspepsia
Insomnia, fatigue
Arthralgia (joint pain), myalgia (muscle pain)
Peripheral edema
Cataract progression
Thrombotic events
Uncommon but Serious:
Hepatotoxicity (elevated bilirubin)
Bone marrow fibrosis (with long-term use)
Hemorrhagic events (paradoxically, due to underlying disease)
Eltrombopag vs. Other Medications
For manufacturers and pharmacies, positioning your product requires understanding the competitive landscape.
vs. Romiplostim (Nplate®): Both are TPO-RAs for ITP. Romiplostim is a peptibody (peptide-Fc fusion protein) administered by weekly subcutaneous injection. Eltrombopag’s key advantage is oral administration. However, romiplostim is not affected by food interactions. The choice often depends on patient preference, insurance coverage, and the physician’s experience.
vs. Avatrombopag (Doptelet®): This is the most direct competitor. Avatrombopag is also an oral, small-molecule TPO-RA. Its significant advantage is that it does not have a food interaction with polyvalent cations, allowing for administration with food and simplifying the dosing regimen. This poses a significant competitive threat and presents a clear target for innovation for both generic and compounded product developers.
vs. Traditional Therapies (Corticosteroids, such as hydrocortisone, and IVIG): While these are first-line treatments, they are often not suitable for long-term use due to significant side effects (steroids) or being transient and expensive (IVIG). Eltrombopag offers a sustainable long-term maintenance option.
Is Eltrombopag safe during pregnancy?
Pregnancy Category C (US FDA). There are no adequate and well-controlled studies in pregnant women.
Animal studies have shown evidence of embryofetal toxicity and reduced fetal weight.
Eltrombopag should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known if eltrombopag is excreted in human milk.
A decision must be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
This information is critical for compounding pharmacies preparing medications for specific patient populations and for including appropriate warnings in labeling.
How long does Eltrombopag take to work?
The onset of action is a key patient counseling point.
Eltrombopag does not produce an immediate increase in platelets.
A response is typically seen within 1 to 2 weeks of initiating therapy.
However, it can take up to 3 or even 4 weeks for some patients to achieve a clinically significant increase in platelet count.
The delayed effect is due to its mechanism of action: it stimulates the production of new megakaryocytes, which then must mature and produce platelets.
This is not an instant process. This timeline is essential for managing patient expectations and for clinical monitoring schedules.
Global Sourcing Tips of Eltrombopag API
This section directly addresses the core pain point of API importers and pharmaceutical manufacturers.
Verify Regulatory Compliance: The number one priority. Source only from manufacturers who are compliant with Good Manufacturing Practices (GMP) as outlined by major regulatory bodies (US FDA, EMA, PMDA, WHO). Demand and verify their Drug Master File (DMF) status (Type II ASMF/Active Substance Master File in Europe). A valid DMF is a non-negotiable starting point.
Rigorous Quality Control (QC) and Certificate of Analysis (CoA): Never accept an API shipment without a comprehensive CoA from an accredited laboratory. The CoA must confirm:
Identity: FTIR, NMR, Mass Spec.
Purity: HPLC/LC-MS must demonstrate≥ 98.5% purity (typically >99% purity is the standard for reputable suppliers).
Related Substances: Clear profiling and quantification of all known and unknown impurities, degradation products, and residual solvents, all within ICH guidelines.
Polymorphic Form: Eltrombopag Olamine can exist in different polymorphic forms. The bioactivity and stability can be form-dependent. The supplier must specify and guarantee the polymorphic form (e.g., Form A, Form B) and provide supporting XRD data.
Supply Chain Transparency and Auditability: Prefer suppliers who allow for audits (on-site or virtual). Understand their supply chain—where the raw materials come from and who their synthesis partners are. Transparency mitigates risk.
Scalability and Reliability: Can the supplier consistently provide the quantities you need, ranging from small R&D batches (grams/kg) to full commercial scale (tens to hundreds of kilograms)? Check their track record and ask for references.
Intellectual Property (IP) and Regulatory Landscape: Ensure the supplier’s manufacturing process does not infringe on existing patents or intellectual property rights. Be aware of the patent expiry status in your target market to plan your generic or compounding strategy effectively.
Compounding Pharmacy Guidelines for Eltrombopag Formulations
For compounding pharmacies, handling Eltrombopag API requires extreme precision and adherence to safety and compatibility protocols.
Legal and Regulatory Framework: Understand the regulations in your jurisdiction (e.g., USP <795> in the U.S.). Compounding with Eltrombopag is typically justified for reasons of dose strength not commercially available (e.g., a 10 mg dose for a pediatric patient), allergen-free formulations, or specific dosage forms (e.g., troches) for patients who cannot swallow tablets.
Handling and Safety: Eltrombopag API is a fine powder. It is a potent drug, and dust generation must be controlled. Use appropriate personal protective equipment (PPE): gloves, mask (N95 or higher), and safety goggles. Work in a controlled environment, such as a laminar flow hood, to protect the operator and prevent cross-contamination.
Formulation Challenges: Remember, it’s BCS Class IV.
Bioavailability is the #1 challenge. Simply crushing tablets or mixing API powder into a suspension may result in sub-therapeutic absorption.
Excipient Selection: Use suspending agents (e.g., xanthan gum) that do not contain polyvalent cations. The vehicle must be free of calcium, magnesium, and iron. Use purified water only.
Taste Masking: The drug is notoriously bitter. Effective taste-masking agents (e.g., sweeteners like sucralose, flavors) are essential for patient compliance, especially in pediatrics.
Stability Studies: You must conduct and document stability studies for your specific formulation to assign a valid beyond-use date (BUD). This is a regulatory requirement.
Patient Counseling: Emphasize the critical administration instructions: on an empty stomach, away from meals and other medications. Provide clear, written instructions with every dispensed compound.
Cost-Effective Bulk Purchasing Strategies for Eltrombopag API Importers
Maximizing ROI on API purchases is crucial for business sustainability.
Strategic Sourcing vs. Spot Buying: For long-term projects, establish strategic partnerships with 2-3 qualified manufacturers. This ensures supply security and often leads to better pricing than one-off spot purchases. Use spot buys only to fill short-term gaps.
Volume Tier Pricing: Negotiate aggressively. Prices per kilogram should decrease significantly as order volumes transition from kilogram to multi-kilogram to commercial batch quantities (e.g., 50 kg+). Don’t hesitate to request formal quotes for different volume tiers.
Total Cost of Ownership (TCO): The cheapest API per kg is often the most expensive in the long run. Factor in the TCO:
Quality: A cheaper, subpar API can lead to failed batches, product recalls, and regulatory action, resulting in significant costs.
Logistics: Include shipping, insurance, and import duties in your cost calculation.
Testing: The cost of in-house or third-party QC testing to verify the CoA.
Long-Term Agreements (LTAs) and Forecasting: Provide your reliable suppliers with realistic, long-term forecasts (12-36 months). This allows them to plan their production, and they will often reward this commitment with preferential pricing and guaranteed allocation.
Geographic Diversification: When considering China and India for cost advantages, also evaluate suppliers from established pharmaceutical regions, such as Europe and North America, for their reliability and regulatory simplicity. A diversified supplier portfolio helps mitigate risks associated with geopolitical and supply chain disruptions.
Eltrombopag Emerging Applications and Future Market Directions
The market for Eltrombopag is dynamic. Staying ahead of the curve is a competitive advantage.
Chemotherapy-Induced Thrombocytopenia (CIT): A significant area of ongoing research. Effective management of CIT could prevent chemotherapy dose reductions or delays, improving oncology outcomes. Positive trial results would massively expand the potential patient population and API demand.
Myelodysplastic Syndromes (MDS): Research is exploring the use of this treatment to improve platelet counts and reduce transfusion dependency in MDS patients.
COVID-19 and Other Viral Illnesses: Thrombocytopenia is a complication of severe COVID-19 and other viral infections. While not a primary treatment, its role is being investigated in specific contexts.
Novel Formulations: The current food interaction is the drug’s biggest drawback. Next-generation formulations are a blue-ocean opportunity. Research into phospholipid complexes, solid dispersions, and nanoparticle-based delivery systems aimed at eliminating the food effect could revolutionize the market. This is a key R&D area for innovative manufacturers.
Conclusion
Eltrombopag Olamine is more than just a molecule; it’s a vital tool in the hematologist’s arsenal and a significant opportunity for the pharmaceutical industry.
Its unique mechanism of action, expanding list of indications, and ongoing research into new applications ensure its continued relevance.
For API importers, success hinges on uncompromising quality control, strategic sourcing, and supply chain resilience.
For medicine manufacturers, mastering the challenges of its BCS Class IV properties through advanced formulation science is the key to developing successful generic or innovative products.
For compounding pharmacies, precision, patient safety, and clear communication are paramount when preparing customized medications.
Navigating the complexities of Eltrombopag—from its clinical nuances to its industrial challenges—requires a partner with deep expertise and a reliable supply chain.
By focusing on quality, innovation, and a thorough understanding of the landscape outlined in this guide, industry professionals can effectively contribute to patient care while building a successful and compliant business around this essential active pharmaceutical ingredient.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
